These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38447700)

  • 1. Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials.
    Blauvelt A; Armstrong A; Merola JF; Strober B; de Cuyper D; Peterson L; Davies O; Stark JL; Lebwohl M
    J Am Acad Dermatol; 2024 Jul; 91(1):72-81. PubMed ID: 38447700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
    J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
    Gordon KB; Langley RG; Warren RB; Okubo Y; Stein Gold L; Merola JF; Peterson L; Wixted K; Cross N; Deherder D; Thaçi D
    JAMA Dermatol; 2022 Jul; 158(7):735-744. PubMed ID: 35544084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
    Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
    Blauvelt A; Papp KA; Merola JF; Gottlieb AB; Cross N; Madden C; Wang M; Cioffi C; Griffiths CEM
    J Am Acad Dermatol; 2020 Nov; 83(5):1367-1374. PubMed ID: 32473974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.
    Glatt S; Helmer E; Haier B; Strimenopoulou F; Price G; Vajjah P; Harari OA; Lambert J; Shaw S
    Br J Clin Pharmacol; 2017 May; 83(5):991-1001. PubMed ID: 27859546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
    Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bimekizumab versus Secukinumab in Plaque Psoriasis.
    Reich K; Warren RB; Lebwohl M; Gooderham M; Strober B; Langley RG; Paul C; De Cuyper D; Vanvoorden V; Madden C; Cioffi C; Peterson L; Blauvelt A
    N Engl J Med; 2021 Jul; 385(2):142-152. PubMed ID: 33891380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bimekizumab versus Adalimumab in Plaque Psoriasis.
    Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
    N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment.
    Abdin R; Gharib R; Bunick CG; Issa NT
    J Drugs Dermatol; 2024 Aug; 23(8):694-696. PubMed ID: 39093648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation.
    Ruggiero A; Potestio L; Martora F; Villani A; Comune R; Megna M
    Expert Opin Drug Saf; 2023; 22(5):355-362. PubMed ID: 37222656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Kimball AB; Jemec GBE; Sayed CJ; Kirby JS; Prens E; Ingram JR; Garg A; Gottlieb AB; Szepietowski JC; Bechara FG; Giamarellos-Bourboulis EJ; Fujita H; Rolleri R; Joshi P; Dokhe P; Muller E; Peterson L; Madden C; Bari M; Zouboulis CC
    Lancet; 2024 Jun; 403(10443):2504-2519. PubMed ID: 38795716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
    Oliver R; Krueger JG; Glatt S; Vajjah P; Mistry C; Page M; Edwards H; Garcet S; Li X; Dizier B; Maroof A; Watling M; El Baghdady A; Baeten D; Ionescu L; Shaw S
    Br J Dermatol; 2022 Apr; 186(4):652-663. PubMed ID: 34687214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bimekizumab for the treatment of psoriatic disease.
    Natsis NE; Gottlieb AB
    Expert Opin Biol Ther; 2018 Dec; 18(12):1193-1197. PubMed ID: 30332893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.
    Burshtein J; Shah M; Zakria D; Armstrong AW; Golant AK; Gottlieb AB; Weinberg JM; Kircik L; Han G; Langley RG; Neimann AL; Lebwohl M
    J Drugs Dermatol; 2024 Aug; 23(8):592-599. PubMed ID: 39093660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
    Reis J; Vender R; Torres T
    BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials.
    Lebwohl MG; Papp KA; Marangell LB; Koo J; Blauvelt A; Gooderham M; Wu JJ; Rastogi S; Harris S; Pillai R; Israel RJ
    J Am Acad Dermatol; 2018 Jan; 78(1):81-89.e5. PubMed ID: 28985956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting.
    Rompoti N; Stefanaki I; Panagakis P; Vavouli C; Politou M; Papoutsaki M; Befon A; Koutsa F; Lazou E; Koumprentziotis IA; Chasapi V; Stratigos A; Nicolaidou E
    Arch Dermatol Res; 2024 Apr; 316(5):133. PubMed ID: 38662223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bimekizumab for psoriasis.
    Rodrigues MA; Freitas E; Torres T
    Drugs Today (Barc); 2022 Jun; 58(6):273-282. PubMed ID: 35670705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.
    Ali Z; Matthews R; Al-Janabi A; Warren RB
    Expert Rev Clin Immunol; 2021 Oct; 17(10):1073-1081. PubMed ID: 34384327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.